As of Thursday close, bluebird bio Inc.’s (NASDAQ:BLUE) stock was down -$0.11, moving down -3.08 percent to $3.46. The average number of shares traded per day over the past five days has been 4,534,960 shares. 5 times new highs have been achieved over the past 5 days, with a $0.08 gain in that time frame. In the last twenty days, the average volume was 4,953,620, while in the previous 50 days, it was 4,555,258.
Since last month, BLUE stock retreated -5.72%. Shares of the company fell to $3.09 on 07/18/23, the lowest level in the past month. A 52-week high of $8.58 was reached on 01/13/23 after having rallying from a 52-week low of $2.78. Since the beginning of this year, BLUE’s stock price has dropped by -50.00% or -$3.46, and marked a new high 6 times. However, the stock has declined by -59.67% since its 52-week high.
BLUE stock investors should be aware that bluebird bio Inc. (BLUE) stock had its last reported insider trading activity 8 days ago on Aug 10. Obenshain Andrew, the President and CEO of the company, disposed of 16,929 shares for $3.54 on Aug 10. It resulted in a $59,956 divestment by the insider. Klima Thomas J sold 4,130 shares at an average price of $3.50 on Jun 02. The insider now owns 133,049 shares following the transaction. On Jan 11, Director Leschly Nick sold 4,290 shares at $7.80 apiece. The transaction was valued at $33,480.
Valuation Metrics
The stock’s beta is 0.91. Besides these, the trailing price-to-sales (P/S) ratio of 40.61, the price-to-book (PB) ratio of 1.30.
Financial Health
In the three months ended June 29, bluebird bio Inc.’s quick ratio stood at 2.00, while its current ratio was 2.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is -37.80% percent. Based on annual data, BLUE earned -$6.48 million in gross profit and brought in $3.6 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -146.30%. Return on equity (ROE) for the past 12 months was -38.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BLUE’s revenue rose 77.94% to $2.38 million during the quarter, while net income inched up to $6.89 million. While analysts expected bluebird bio Inc. to report -$0.72 quarterly earnings, the actual figure was -$0.67 per share, beating the consensus estimate by 6.90%. During the quarter, the company generated -$84.33 million in EBITDA. The liabilities of bluebird bio Inc. were 374.37 million at the end of its most recent quarter ended June 29, and its total debt was $306.86 million. The value of shareholders’ equity is $106.95 million.
Technical Picture
This quick technical analysis looks at bluebird bio Inc.’s (BLUE) price momentum. With a historical volatility rate of 89.90%, the RSI 9-day stood at 44.83% on 17 August.
With respect to its five-day moving average, the current bluebird bio Inc. price is up by +2.37% percent or $0.08. At present, BLUE shares trade -1.42% below its 20-day simple moving average and -21.90% percent below its 100-day simple moving average. However, the stock is currently trading approximately -7.24% below its SMA50 and -44.55% below its SMA200.
Stochastic coefficient K was 34.65% and Stochastic coefficient D was 30.91%, while ATR was 0.35. Given the Stochastic reading of 27.56% for the 14-day period, the RSI (14) reading has been calculated as 46.61%. As of today, the MACD Oscillator reading stands at 0.02, while the 14-day reading stands at -0.09.
Analyst Ratings
BofA Securities upgraded its rating on bluebird bio Inc. (NASDAQ: BLUE) to a Buy in a note to investors on July 19, 2023. The analysts firm previously had a Neutral rating on the stock.bluebird bio Inc. (BLUE) has been rated Hold by analysts. According to 2 brokerage firms, BLUE is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate bluebird bio Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $3.00 – $11.00. Based on these forecasts, analysts predict bluebird bio Inc. (BLUE) will achieve an average price target of $7.36.
